Loading…

In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines

Background: Although the anti-tumour effect of cyclooxygenase-2 (Cox-2) inhibitors in invasive bladder cancer has been confirmed, its mechanisms of action are unclear. Recently, the concept of an epithelial-to-mesenchymal transition (EMT) promoting carcinoma progression has been suggested, and a key...

Full description

Saved in:
Bibliographic Details
Published in:British journal of cancer 2011-07, Vol.105 (3), p.393-402
Main Authors: Adhim, Z, Matsuoka, T, Bito, T, Shigemura, K, Lee, K-M, Kawabata, M, Fujisawa, M, Nibu, K, Shirakawa, T
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273
cites cdi_FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273
container_end_page 402
container_issue 3
container_start_page 393
container_title British journal of cancer
container_volume 105
creator Adhim, Z
Matsuoka, T
Bito, T
Shigemura, K
Lee, K-M
Kawabata, M
Fujisawa, M
Nibu, K
Shirakawa, T
description Background: Although the anti-tumour effect of cyclooxygenase-2 (Cox-2) inhibitors in invasive bladder cancer has been confirmed, its mechanisms of action are unclear. Recently, the concept of an epithelial-to-mesenchymal transition (EMT) promoting carcinoma progression has been suggested, and a key feature of the EMT is the downregulation of E-cadherin. In this study, we investigated the effect of Cox-2 inhibitors on reversal EMT and tumour growth inhibition in bladder cancer cells. Methods: We used three Cox-2 inhibitors, etodolac, celecoxib and NS-398 and three human bladder cancer cell lines, T24, 5637 and KK47, in this study. T24 xenograft tumour mouse model was used in the in vivo study. Results: Within the clinical drug concentrations, only etodolac showed the in vitro growth inhibition in T24 not in the other cell lines. Etodolac reduced SNAIL mRNA and vimentin cell surface expression, and induced E-cadherin mRNA and E-cadherin cell surface expression, in T24. Etodolac also most strongly inhibited the cell migration of T24 in vitro and showed the highest tumour growth inhibition in T24 tumour in vivo . Conclusion: Etodolac at clinical doses exhibited induced in vitro and in vivo anti-tumour effects and reversal effect of EMT in T24. These results suggest that etodolac is a good candidate for an anti-tumour or chemopreventive reagent for high-grade bladder cancer.
doi_str_mv 10.1038/bjc.2011.262
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3172915</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2408052521</sourcerecordid><originalsourceid>FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273</originalsourceid><addsrcrecordid>eNptkU2LFDEQhoMo7jh68yxBEC_2mKQ_c1mQwY-FBS96Dumksp0hnYxJ9-D8B3-0aWfcUfFUFPXkzVv1IvSckg0lZfe236kNI5RuWMMeoBWtS1bQjrUP0YoQ0haEM3KFnqS0yy0nXfsYXTHa1qSuyQr9uPH4YKcYsPQa26U5hFwH29spxCMGY0BNOBg8DREAb8P3gl2A9Osd7O00gLPSFVMoRkjg1XAcpcNTlD7ZyQa_iA_zKD3undQaIlbSq6WAc9hZD-kpemSkS_DsXNfo64f3X7afitvPH2-2724LVVfVVFAGQGVDVcc16zvgpGlqTWquSsVBk1IZw6ihqpJaaWm0rkqmuWmJNh1nbblG1yfd_dyPoBX4bNOJfbSjjEcRpBV_T7wdxF04iJK2jOcLr9Hrs0AM32ZIkxhtWvaQHsKcRNfypm1IW2by5T_kLszR5-0WiLKa8wV6c4JUDClFMPdWKBFLyCKHLJaQRQ454y_-tH8P_041A6_OgExKOpMzUDZduKqiPF8yc8WJS3nk7yBezP334593e8HE</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>879125993</pqid></control><display><type>article</type><title>In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines</title><source>PubMed Central Free</source><creator>Adhim, Z ; Matsuoka, T ; Bito, T ; Shigemura, K ; Lee, K-M ; Kawabata, M ; Fujisawa, M ; Nibu, K ; Shirakawa, T</creator><creatorcontrib>Adhim, Z ; Matsuoka, T ; Bito, T ; Shigemura, K ; Lee, K-M ; Kawabata, M ; Fujisawa, M ; Nibu, K ; Shirakawa, T</creatorcontrib><description>Background: Although the anti-tumour effect of cyclooxygenase-2 (Cox-2) inhibitors in invasive bladder cancer has been confirmed, its mechanisms of action are unclear. Recently, the concept of an epithelial-to-mesenchymal transition (EMT) promoting carcinoma progression has been suggested, and a key feature of the EMT is the downregulation of E-cadherin. In this study, we investigated the effect of Cox-2 inhibitors on reversal EMT and tumour growth inhibition in bladder cancer cells. Methods: We used three Cox-2 inhibitors, etodolac, celecoxib and NS-398 and three human bladder cancer cell lines, T24, 5637 and KK47, in this study. T24 xenograft tumour mouse model was used in the in vivo study. Results: Within the clinical drug concentrations, only etodolac showed the in vitro growth inhibition in T24 not in the other cell lines. Etodolac reduced SNAIL mRNA and vimentin cell surface expression, and induced E-cadherin mRNA and E-cadherin cell surface expression, in T24. Etodolac also most strongly inhibited the cell migration of T24 in vitro and showed the highest tumour growth inhibition in T24 tumour in vivo . Conclusion: Etodolac at clinical doses exhibited induced in vitro and in vivo anti-tumour effects and reversal effect of EMT in T24. These results suggest that etodolac is a good candidate for an anti-tumour or chemopreventive reagent for high-grade bladder cancer.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2011.262</identifier><identifier>PMID: 21750550</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/80/84/2176 ; 631/92/436/2388 ; 692/308/575 ; 692/699/67/589/1336 ; Animals ; Antineoplastic Agents - pharmacology ; Apoptosis - drug effects ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Bladder cancer ; Cadherins - metabolism ; Cancer Research ; Cell Dedifferentiation ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Cyclooxygenase 2 Inhibitors - pharmacology ; Drug Resistance ; Epidemiology ; Epithelial-Mesenchymal Transition ; Etodolac - pharmacology ; Humans ; Medical sciences ; Mice ; Mice, Nude ; Molecular Medicine ; Nephrology. Urinary tract diseases ; Oncology ; Translational Therapeutics ; Tumors ; Tumors of the urinary system ; Urinary Bladder Neoplasms ; Urinary tract. Prostate gland ; Vimentin - metabolism ; Xenograft Model Antitumor Assays</subject><ispartof>British journal of cancer, 2011-07, Vol.105 (3), p.393-402</ispartof><rights>The Author(s) 2011</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Jul 26, 2011</rights><rights>Copyright © 2011 Cancer Research UK 2011 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273</citedby><cites>FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172915/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3172915/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=24419544$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21750550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adhim, Z</creatorcontrib><creatorcontrib>Matsuoka, T</creatorcontrib><creatorcontrib>Bito, T</creatorcontrib><creatorcontrib>Shigemura, K</creatorcontrib><creatorcontrib>Lee, K-M</creatorcontrib><creatorcontrib>Kawabata, M</creatorcontrib><creatorcontrib>Fujisawa, M</creatorcontrib><creatorcontrib>Nibu, K</creatorcontrib><creatorcontrib>Shirakawa, T</creatorcontrib><title>In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background: Although the anti-tumour effect of cyclooxygenase-2 (Cox-2) inhibitors in invasive bladder cancer has been confirmed, its mechanisms of action are unclear. Recently, the concept of an epithelial-to-mesenchymal transition (EMT) promoting carcinoma progression has been suggested, and a key feature of the EMT is the downregulation of E-cadherin. In this study, we investigated the effect of Cox-2 inhibitors on reversal EMT and tumour growth inhibition in bladder cancer cells. Methods: We used three Cox-2 inhibitors, etodolac, celecoxib and NS-398 and three human bladder cancer cell lines, T24, 5637 and KK47, in this study. T24 xenograft tumour mouse model was used in the in vivo study. Results: Within the clinical drug concentrations, only etodolac showed the in vitro growth inhibition in T24 not in the other cell lines. Etodolac reduced SNAIL mRNA and vimentin cell surface expression, and induced E-cadherin mRNA and E-cadherin cell surface expression, in T24. Etodolac also most strongly inhibited the cell migration of T24 in vitro and showed the highest tumour growth inhibition in T24 tumour in vivo . Conclusion: Etodolac at clinical doses exhibited induced in vitro and in vivo anti-tumour effects and reversal effect of EMT in T24. These results suggest that etodolac is a good candidate for an anti-tumour or chemopreventive reagent for high-grade bladder cancer.</description><subject>631/80/84/2176</subject><subject>631/92/436/2388</subject><subject>692/308/575</subject><subject>692/699/67/589/1336</subject><subject>Animals</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bladder cancer</subject><subject>Cadherins - metabolism</subject><subject>Cancer Research</subject><subject>Cell Dedifferentiation</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Cyclooxygenase 2 Inhibitors - pharmacology</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Epithelial-Mesenchymal Transition</subject><subject>Etodolac - pharmacology</subject><subject>Humans</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Molecular Medicine</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Oncology</subject><subject>Translational Therapeutics</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary Bladder Neoplasms</subject><subject>Urinary tract. Prostate gland</subject><subject>Vimentin - metabolism</subject><subject>Xenograft Model Antitumor Assays</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><recordid>eNptkU2LFDEQhoMo7jh68yxBEC_2mKQ_c1mQwY-FBS96Dumksp0hnYxJ9-D8B3-0aWfcUfFUFPXkzVv1IvSckg0lZfe236kNI5RuWMMeoBWtS1bQjrUP0YoQ0haEM3KFnqS0yy0nXfsYXTHa1qSuyQr9uPH4YKcYsPQa26U5hFwH29spxCMGY0BNOBg8DREAb8P3gl2A9Osd7O00gLPSFVMoRkjg1XAcpcNTlD7ZyQa_iA_zKD3undQaIlbSq6WAc9hZD-kpemSkS_DsXNfo64f3X7afitvPH2-2724LVVfVVFAGQGVDVcc16zvgpGlqTWquSsVBk1IZw6ihqpJaaWm0rkqmuWmJNh1nbblG1yfd_dyPoBX4bNOJfbSjjEcRpBV_T7wdxF04iJK2jOcLr9Hrs0AM32ZIkxhtWvaQHsKcRNfypm1IW2by5T_kLszR5-0WiLKa8wV6c4JUDClFMPdWKBFLyCKHLJaQRQ454y_-tH8P_041A6_OgExKOpMzUDZduKqiPF8yc8WJS3nk7yBezP334593e8HE</recordid><startdate>20110726</startdate><enddate>20110726</enddate><creator>Adhim, Z</creator><creator>Matsuoka, T</creator><creator>Bito, T</creator><creator>Shigemura, K</creator><creator>Lee, K-M</creator><creator>Kawabata, M</creator><creator>Fujisawa, M</creator><creator>Nibu, K</creator><creator>Shirakawa, T</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110726</creationdate><title>In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines</title><author>Adhim, Z ; Matsuoka, T ; Bito, T ; Shigemura, K ; Lee, K-M ; Kawabata, M ; Fujisawa, M ; Nibu, K ; Shirakawa, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>631/80/84/2176</topic><topic>631/92/436/2388</topic><topic>692/308/575</topic><topic>692/699/67/589/1336</topic><topic>Animals</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bladder cancer</topic><topic>Cadherins - metabolism</topic><topic>Cancer Research</topic><topic>Cell Dedifferentiation</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Cyclooxygenase 2 Inhibitors - pharmacology</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Epithelial-Mesenchymal Transition</topic><topic>Etodolac - pharmacology</topic><topic>Humans</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Molecular Medicine</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Oncology</topic><topic>Translational Therapeutics</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary Bladder Neoplasms</topic><topic>Urinary tract. Prostate gland</topic><topic>Vimentin - metabolism</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adhim, Z</creatorcontrib><creatorcontrib>Matsuoka, T</creatorcontrib><creatorcontrib>Bito, T</creatorcontrib><creatorcontrib>Shigemura, K</creatorcontrib><creatorcontrib>Lee, K-M</creatorcontrib><creatorcontrib>Kawabata, M</creatorcontrib><creatorcontrib>Fujisawa, M</creatorcontrib><creatorcontrib>Nibu, K</creatorcontrib><creatorcontrib>Shirakawa, T</creatorcontrib><collection>SpringerOpen (Open Access)</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adhim, Z</au><au>Matsuoka, T</au><au>Bito, T</au><au>Shigemura, K</au><au>Lee, K-M</au><au>Kawabata, M</au><au>Fujisawa, M</au><au>Nibu, K</au><au>Shirakawa, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2011-07-26</date><risdate>2011</risdate><volume>105</volume><issue>3</issue><spage>393</spage><epage>402</epage><pages>393-402</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background: Although the anti-tumour effect of cyclooxygenase-2 (Cox-2) inhibitors in invasive bladder cancer has been confirmed, its mechanisms of action are unclear. Recently, the concept of an epithelial-to-mesenchymal transition (EMT) promoting carcinoma progression has been suggested, and a key feature of the EMT is the downregulation of E-cadherin. In this study, we investigated the effect of Cox-2 inhibitors on reversal EMT and tumour growth inhibition in bladder cancer cells. Methods: We used three Cox-2 inhibitors, etodolac, celecoxib and NS-398 and three human bladder cancer cell lines, T24, 5637 and KK47, in this study. T24 xenograft tumour mouse model was used in the in vivo study. Results: Within the clinical drug concentrations, only etodolac showed the in vitro growth inhibition in T24 not in the other cell lines. Etodolac reduced SNAIL mRNA and vimentin cell surface expression, and induced E-cadherin mRNA and E-cadherin cell surface expression, in T24. Etodolac also most strongly inhibited the cell migration of T24 in vitro and showed the highest tumour growth inhibition in T24 tumour in vivo . Conclusion: Etodolac at clinical doses exhibited induced in vitro and in vivo anti-tumour effects and reversal effect of EMT in T24. These results suggest that etodolac is a good candidate for an anti-tumour or chemopreventive reagent for high-grade bladder cancer.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>21750550</pmid><doi>10.1038/bjc.2011.262</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-0920
ispartof British journal of cancer, 2011-07, Vol.105 (3), p.393-402
issn 0007-0920
1532-1827
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3172915
source PubMed Central Free
subjects 631/80/84/2176
631/92/436/2388
692/308/575
692/699/67/589/1336
Animals
Antineoplastic Agents - pharmacology
Apoptosis - drug effects
Biological and medical sciences
Biomedical and Life Sciences
Biomedicine
Bladder cancer
Cadherins - metabolism
Cancer Research
Cell Dedifferentiation
Cell Line, Tumor
Cell Proliferation - drug effects
Cyclooxygenase 2 Inhibitors - pharmacology
Drug Resistance
Epidemiology
Epithelial-Mesenchymal Transition
Etodolac - pharmacology
Humans
Medical sciences
Mice
Mice, Nude
Molecular Medicine
Nephrology. Urinary tract diseases
Oncology
Translational Therapeutics
Tumors
Tumors of the urinary system
Urinary Bladder Neoplasms
Urinary tract. Prostate gland
Vimentin - metabolism
Xenograft Model Antitumor Assays
title In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T12%3A38%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20and%20in%20vivo%20inhibitory%20effect%20of%20three%20Cox-2%20inhibitors%20and%20epithelial-to-mesenchymal%20transition%20in%20human%20bladder%20cancer%20cell%20lines&rft.jtitle=British%20journal%20of%20cancer&rft.au=Adhim,%20Z&rft.date=2011-07-26&rft.volume=105&rft.issue=3&rft.spage=393&rft.epage=402&rft.pages=393-402&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2011.262&rft_dat=%3Cproquest_pubme%3E2408052521%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c544t-12ee1a61c89d2b8e90665d059c3c9ed03cff21f1c4adcdafdd432d9f70df89273%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=879125993&rft_id=info:pmid/21750550&rfr_iscdi=true